Sintilimab, a fully human IgG4 monoclonal antibody which binds to PD‐1 to block the interaction of PD‐1 with PD‐L1 and PD‐L2, has been approved in China to treat patients with relapsed or refractory Hodgkin’s lymphoma (63). The gene discussed is CD274; the disease is Hodgkins lymphoma.